Urinary incontinence doesn’t have to be a way of life.
No drugs, just relief.

Now Enrolling Participants | Register Below to see if You Qualify

Participating in Future Research Studies

Would you like to be contacted in the future about participating in additional research studies?

PLEASE NOTE: Your decision about being contacted for future studies will not impact your opportunity to participate in the current study.



Compensation up to $450 upon
study completion


Females - 18+ with UI symptoms


An 8-week study


United States

What Will I Have to Do?

Fill out our form

Fill the questionnaire above to do the basic qualification assessment

Talk to our representative

If qualified, one of our staff members will contact you to guide during the enrollment process on the study

Get Started!

This study involves an 8-weeks consecutive daily diary update using our app.


If you are selected to participate in this study, you will be randomly assigned to the Leva or Kegel group. Both groups will be asked to complete pelvic floor muscle exercises (often referred to as "Kegels") three times a day (a 5-minute task) and record the results using an app. For additional compensation, participants will be asked to complete an additional survey at 6 and 12 months post-study.
No! You can download the study app to your phone, and participants in the device study group will be mailed the Leva.
Participants will receive up to $450 upon study completion
Yes! The Leva has been cleared by the FDA and available by prescription.
Yes, although you will only receive compensation based on the milestones you hit before dropping out.

Meet the Experts

Holly E. Richter, PhD, MD

She is the J Marion Sims Endowed Chair and Professor of Obstetrics and Gynecology, Urology & Geriatrics at the University of Alabama at Birmingham. She is Research Director of the Division of Urogynecology and Pelvic Reconstructive Surgery, as well as Director of the Urogynecology Care and Genito-rectal Disorders Clinics and Ambulatory Clinics.

She is past President of the Society of Gynecologic Surgeons and President-elect of the American Urogynecologic Society. She currently serves as an Editor of International Urogynecology Journal. She was the Principal Investigator of the NIDDK-sponsored Urinary Incontinence Treatment Network and a PI of the NICHD-sponsored Pelvic Floor Disorders Network. She oversees other NIH and industry sponsored research. She was also the recipient of a 10-year mid-career award (K24-NIDDK) in patient oriented pelvic floor research and mentors many investigators.

Dr Richter has received numerous awards and is involved in didactic and research initiatives with residents, medical students, and fellows. She has authored over 300 peer-reviewed papers. Dr Richter has a strong interest in treating vesicovaginal fistulas and serves on the Board of Directors of the World-Wide Fistula Fund.

Milena Weinstein, MD

She is Assistant Professor of Obstetrics, Gynecology and Reproductive Medicine at Harvard Medical School. She is the Director of the Fellowship training program in the division of Female Pelvic Medicine and Reconstructive Surgery at Massachusetts General Hospital, where she has worked since 2008. She completed a fellowship in Female Pelvic Medicine and Reconstructive Surgery at the University of California San Diego School of Medicine. She completed medical school and Obstetrics and Gynecology residency at University of California Los Angeles.

She is a co-chair of the Mass General Center for Pelvic Floor Disorders, a multidisciplinary group comprised of pelvic reconstructive surgeons, colorectal surgeons, urologists, gastroenterologists and physical therapists.

Dr. Weinstein has served on multiple national committees at American Urogynecologic Society (AUGS). She also has been trained in three-dimensional pelvic floor ultrasound. She teaches on pelvic floor ultrasound nationally and uses pelvic floor ultrasound for research and to assist with diagnosis and treatment.

Please note: ObvioHealth may store your data in a confidential and secure database. That personal information will never be shared or sold with any other persons or organizations not associated with ObvioHealth. ObvioHealth may/will use personal information to contact you directly by phone and/or email for matters related to potential participation in clinical trials for which the potential subject may qualify.